Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
28.05. | OnKure Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
06.05. | OnKure Therapeutics GAAP EPS of $1.19 | 1 | Seeking Alpha | ||
06.05. | OnKure Therapeutics, Inc. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
06.05. | OnKure Therapeutics, Inc.: OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights | 105 | GlobeNewswire (Europe) | -- Continued progress in the PIKture-01 trial; on track to report additional data in the second half of 2025, including mature single agent and initial combination data -- Expansion of the Company's... ► Artikel lesen | |
ONKURE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
06.05. | OnKure Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
30.04. | Evercore ISI starts OnKure stock with Outperform rating | 1 | Investing.com | ||
18.03. | H.C. Wainwright cuts OnKure Therapeutics price target to $34 | 8 | Investing.com | ||
10.03. | OnKure Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
10.03. | OnKure Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
10.03. | OnKure Therapeutics, Inc.: OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights | 215 | GlobeNewswire (Europe) | - PIKture-01 trial update including additional PK data, mature single agent and initial combination data expected in the second half of 2025; reported encouraging preliminary data in December 2024... ► Artikel lesen | |
10.03. | OnKure Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
10.12.24 | OnKure reports positive early trial data for cancer drug OKI-219 | 1 | Investing.com | ||
10.12.24 | OnKure meldet positive frühe Studiendaten für Krebsmedikament OKI-219 | 3 | Investing.com Deutsch | ||
10.12.24 | OnKure Therapeutics, Inc.: OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219 | 171 | GlobeNewswire (Europe) | -- OKI-219 is well-tolerated across all doses, and no dose interruptions, delays, reductions, or discontinuations were reported -- Initial patient data show exposures of OKI-219 exceeding levels associated... ► Artikel lesen | |
10.12.24 | OnKure Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
09.12.24 | OnKure Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
04.10.24 | OnKure Therapeutics, Inc. Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million | 255 | GlobeNewswire (Europe) | -- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Ka), initially in breast cancer -- On track to announce early clinical... ► Artikel lesen | |
03.10.24 | Reneo Pharmaceuticals, Inc.: Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure | 229 | GlobeNewswire (Europe) | - Combined company to trade on Nasdaq under ticker "OKUR" - Reneo announces 1-for-10 reverse split of common stock IRVINE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq:... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PFIZER | 20,510 | +0,15 % | Goldgrube US-Gesundheitswandel: Wie sind Bayer, PanGenomic Health und Pfizer aufgestellt? | Das US-Gesundheitswesen erlebt unter Minister Robert F. Kennedy Jr. einen beispiellosen Umbruch. Pharmariesen ächzen unter drastischen Preiskontrollen und regulatorischen Erdbeben, während digitale... ► Artikel lesen | |
SANOFI | 89,11 | +0,01 % | Sanofi SA-Aktie unter Druck: Kurs fällt um 4,11 Prozent (87,2414 €) | Keinen Grund zur Freude haben die Investoren von Sanofi SA : Der Kurs des Papiers sackt kräftig ab. Das Wertpapier von Sanofi SA gehört heute mit einem Minus von 4,11 Prozent zu den Werten mit den größten... ► Artikel lesen | |
INNOCAN PHARMA | 0,111 | +2,31 % | Unglaubliche Prognose für Montag setzt Innocan Pharma Aktionäre unter Druck. Jetzt Sondermeldung lesen und Montag reagieren! | ||
ASSEMBLY BIOSCIENCES | 14,200 | 0,00 % | Assembly Biosciences: "Es ist ein großes Jahr für uns" | Mein Top-Favorit 2025 setzt zur Rallye an: +90% Kursgewinn innerhalb der letzten zwei Monate können erst der Anfang sein. Assembly Biosciences (WKN: A402CB) steht vor entscheidenden sechs Monaten. Sämtliche... ► Artikel lesen | |
NEKTAR THERAPEUTICS | 0,602 | +3,35 % | XFRA ISIN CHANGE | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenUS0977021049 Bolt Biotherapeutics Inc. 06.06.2025 US0977022039 Bolt Biotherapeutics Inc. 09.06.2025 Tausch 20:1SE0018041097 Spotr... ► Artikel lesen | |
JAGUAR HEALTH | 3,885 | -2,88 % | Jaguar Health, Inc.: Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners' Spring 2025 Spotlight Series | Click here to register SAN FRANCISCO, CA / ACCESS Newswire / June 6, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will participate... ► Artikel lesen | |
ROYALTY PHARMA | 29,670 | +0,07 % | Dividendenbekanntmachungen (16.05.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADIDAS AG DE000A1EWWW0 - 2 EUR AF GRUPPEN ASA NO0003078107 5 NOK 0,4289 EUR AIXTRON SE DE000A0WMPJ6 - 0,15 EUR ALGOMA CENTRAL CORPORATION CA0156441077 0... ► Artikel lesen | |
BRIDGEBIO PHARMA | 34,450 | +1,71 % | Piper Sandler maintains overweight rating on BridgeBio Pharma stock | ||
CORBUS PHARMACEUTICALS | 8,100 | 0,00 % | Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity | CB1 inverse agonism is a clinically validated mechanism to induce weight loss CRB-913 is markedly more peripherally restricted compared to monlunabant and rimonabantSAD/MAD Phase 1 trial scheduled... ► Artikel lesen | |
SOLIGENIX | 1,880 | +1,08 % | SOLIGENIX, INC.: Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results | PRINCETON, N.J., May 9, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing... ► Artikel lesen | |
KALA BIO | 3,618 | -0,06 % | Oppenheimer nimmt Kala Bio-Aktie mit Outperform-Bewertung auf | ||
NEUROGENE | 19,850 | 0,00 % | Stifel maintains Buy on Neurogene stock, target at $46 | ||
ACLARIS THERAPEUTICS | 1,416 | +5,12 % | Aclaris Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
ESSA PHARMA | 1,705 | -0,29 % | ESSA Pharma Inc: ESSA Pharma Reports Financial Results for Fiscal Second Quarter Ended March 31, 2025 | Company continues to explore and review strategic options focused on maximizing shareholder value
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, May 8, 2025 ... ► Artikel lesen | |
LYRA THERAPEUTICS | 24,275 | -4,16 % | Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS) | ENLIGHTEN 2 trial met primary endpoint with LYR-210 demonstrating statistically significant improvement in the composite of the three cardinal symptoms (3CS) of CRS at 24 weeks (p=0.0078)ENLIGHTEN... ► Artikel lesen |